miRNA-145在前列腺癌中的表达及临床意义
发布时间：2019-01-21 07:28
【摘要】：目的探讨miRNA-145在前列腺癌中的表达及其与临床病理参数、预后的关系。方法前列腺癌患者120例为研究组,良性前列腺增生患者120例为对照组,通过免疫组织化学方法检测两组miRNA-145的表达,分析miRNA-145的表达与研究组临床参数及预后的关系。结果研究组miRNA-145的阳性表达率较对照组降低(P0.05),miRNA-145的表达与患者年龄、临床分期、精囊浸润无关(P0.05);而与前列腺特异抗原(PSA)、是否有淋巴结转移、Gleason评分有关(P0.05)。miRNA-145阳性表达患者的无进展生存率较miRNA-145阴性表达患者升高(P0.05)。结论miRNA-145在前列腺癌组织中表达下调,其表达与前列腺癌组织的浸润、转移及预后有关,这显示miRNA-145可以作为一种新的分子靶点用于前列腺癌治疗及预后评估。
[Abstract]:Objective to investigate the expression of miRNA-145 in prostate cancer and its relationship with clinicopathologic parameters and prognosis. Methods 120 patients with prostate cancer and 120 patients with benign prostatic hyperplasia as control group were studied. The expression of miRNA-145 was detected by immunohistochemistry, and the relationship between the expression of miRNA-145 and the clinical parameters and prognosis of the study group was analyzed. Results the positive expression rate of miRNA-145 in the study group was lower than that in the control group (P0.05). The expression of miRNA-145 was not related to the patient's age, clinical stage and seminal vesicle infiltration (P0.05). However, the Gleason score was related to whether the prostate specific antigen (PSA),) had lymph node metastasis or not (P0.05). The progression-free survival rate of the patients with positive miRNA-145 expression was higher than that of the patients with miRNA-145 negative expression (P0.05). Conclusion the expression of miRNA-145 is down-regulated in prostate cancer tissues, and its expression is related to the invasion, metastasis and prognosis of prostate cancer, which suggests that miRNA-145 can be used as a new molecular target for the treatment and prognosis evaluation of prostate cancer.
【作者单位】： 华中科技大学同济医学院附属武汉中心医院泌尿外科;
【分类号】：R737.25
，
本文编号：2412437
[Abstract]:Objective to investigate the expression of miRNA-145 in prostate cancer and its relationship with clinicopathologic parameters and prognosis. Methods 120 patients with prostate cancer and 120 patients with benign prostatic hyperplasia as control group were studied. The expression of miRNA-145 was detected by immunohistochemistry, and the relationship between the expression of miRNA-145 and the clinical parameters and prognosis of the study group was analyzed. Results the positive expression rate of miRNA-145 in the study group was lower than that in the control group (P0.05). The expression of miRNA-145 was not related to the patient's age, clinical stage and seminal vesicle infiltration (P0.05). However, the Gleason score was related to whether the prostate specific antigen (PSA),) had lymph node metastasis or not (P0.05). The progression-free survival rate of the patients with positive miRNA-145 expression was higher than that of the patients with miRNA-145 negative expression (P0.05). Conclusion the expression of miRNA-145 is down-regulated in prostate cancer tissues, and its expression is related to the invasion, metastasis and prognosis of prostate cancer, which suggests that miRNA-145 can be used as a new molecular target for the treatment and prognosis evaluation of prostate cancer.
【作者单位】： 华中科技大学同济医学院附属武汉中心医院泌尿外科;
【分类号】：R737.25
，
本文编号：2412437
本文链接：https://www.wllwen.com/yixuelunwen/mjlw/2412437.html
最近更新
教材专著
